Femoral FracturePhase 2NCT06050668
Essential Amino Acid Supplementation for Femoral Fragility Fractures
A Phase 2 study testing Essential Amino Acid Supplementation in people with Femoral Fracture and Fragility Fracture, run by Michael C Willey at 2 sites in United States.
Trial summary
This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber… Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Femoral Fracture, Fragility Fracture, Muscle Atrophy
- What is being tested?
- Essential Amino Acid Supplementation
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 2 sitesUnited States
- Study dates
- 17 Jun 2024to Dec 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Hospital inpatient
- Age ≥ 65 years old on admission
- Low-energy mechanism of injury
- Diagnosis of femur fracture (OTA 31, 32, or 33 fracture)
- Indicated for surgical fixation
- Able to provide informed consent
Who cannot join
- Part of a vulnerable population (ex: Incarcerated, Non-English speaking)
- Cognitive impairment (MMSE score ≤ 17)
- Electrical medical implant (ex: Pacemaker/Defibrillator, Left Ventricular Assist Device, Cochlear implant, Insulin pump, Pain medication pumps, Spinal cord stimulator)
- Non-ambulatory prior to injury
- Inability to consume an oral diet or allergy to supplement ingredients (ex: milk allergy)
- Concern for inability to complete follow-up
- Hemi or total arthroplasty (joint replacement)
- Patients with a historical diagnosis of chronic kidney disease (CKD)
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Not yet recruiting
Slocum Center for Orthopedics & Sports Medicine
Eugene, Oregon, 97401
Tessa Kirkpatrick, 5418680658, tessa.kirkpatrick@slocumfoundation.org
- Recruiting
University of Iowa Health Care
Iowa City, Iowa, 52242
Ashley S Kochuyt, BS, ashley-kochuyt@uiowa.edu
About this study
Official title: MEND Repair & Recover Clinical Trial
This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.
Read the detailed description
This study consists of 7 study visits that occur over 6 months after operative fixation of femoral fragility fracture. Consenting participants will be asked to complete the study assessments/procedures at the time points described below. Patients will be treated with operative fixation of their fracture per standard of care.
Preoperative
- Mini-Mental State Examination (MMSE-2®): This is a screening tool for cognitive impairment and will be used to determine eligibility for the study.
- Subjects will be randomized to the intervention arm or control arm in a 1:1 ratio. Subjects randomized to the control arm will receive standard of care nutrition during hospital admission. Subjects randomized to intervention arm of this study will receive essential amino acid (EAA)-based oral nutrition supplementation in addition to standard of care nutrition. Subjects will take the supplement twice daily for 4 weeks after injury. Supplementation will begin within 72 hours of surgical fixation.
Day of Surgery (DOS):
- Muscle Biopsy: Bilaterial biopsies will be obtained from the superficial vastus lateralis muscle on the injury extremity. Biopsies will be performed by board-certified orthopedic surgeons.
- Systemic Inflammatory Labs: A sample of about 15 mL of peripheral venous blood will be obtained by trained clinical staff.
Postoperative Day 1 (POD 1)
- Body composition: Will be assessed using a bioelectrical impedance analysis (BIA) device (InBody S10 Body Composition Analyzer). This is non-invasive test that uses a low-level imperceptible electrical current to measure body composition and body water. In a supine position, electrodes are placed on the hands and ankles of the subjects and the result is recorded in the BIA device. This assessment will be performed by trained study team members.
- Visual Analog Scale (VAS): This is a survey to report on subjective pain.
- Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function: This is a survey that asks subjects to report on subjective measures of pain and physical function. This survey is a computer adaptive test that is completed in REDCap® using a tablet or computer. Subjects will self-administer this survey
- Mini Nutrition Assessment (MNA): This is a survey designed for elderly patients to identify malnourishment or risk thereof. This survey is a computer adaptive test that is completed in REDCap® using a tablet or computer.
- Protein Screener: This is a survey designed for older adults to screen for low protein intake. This survey is a computer adaptive test that is completed in REDCap® using a tablet or computer.
- Barthel Activities of Daily Living Index is a commonly used measure of activities of daily living outcomes for older adults. It measures the ability to perform activities of daily living that are important for maintaining function including feeding, bathing, grooming, dressing, bowel control, bladder control, toilet use, transfers from bed to chair and back, mobility on level surfaces, and stairs. Each measure is assessed on a 10-point scale, all scores are combined to give a score out of 100 points. The higher the score the more independent the individual.
- Residence at a nursing home will be recorded at each follow up visit. Participants living in an assisted living home (apartment or condominium with nursing assistance on call), apartment, single family home, or family member's home are considered living in the community.
- Patients will be given an adverse event log to track any side effects or falls. We will encourage patients to call us but would like them to have a note sheet in case they forget.
- Patients randomized to the supplement group will be given a take home supplement log where they will track their AM and PM doses.
- All patients will be given logs to keep track of their daily pain, PT and number of meals eaten. 3 Week Clinic Visit:
- Muscle biopsies
- Systemic inflammatory labs
- Body composition: InBody S10 Body Composition Analyzer
- Visual Analog Scale (VAS)
- Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function
- Barthel Activities of Daily Living Index
- Residence at a nursing home.
- Supplement Compliance: Patients will be asked to return completed log sheets and if they were randomized to the supplement group, being in their supplement containers to be weighed. 6-Week Clinic Visit:
- Body composition: InBody S10 Body Composition Analyzer
- Visual Analog Scale (VAS)
- PROMIS Physical Function
- Barthel Activities of Daily Living Index
- Residence at a nursing home
- Supplement compliance 12-week Clinic Visit:
- Body composition: InBody S10 Body Composition Analyzer
- Visual Analog Scale (VAS)
- PROMIS Physical Function
- Mini Nutrition Assessment (MNA)
- Protein Screener
- Barthel Activities of Daily Living Index
- Residence at a nursing home
- Physical Performance Measures: Objective measures of physical performance (mobility, strength, power, \& balance) will be assessed with the Short Physical Performance Battery (SPPB)14 and the Timed Up \& Go (TUG)15 test. During the SPPB, subjects will complete the following physical assessments - ability to stand for 10 seconds with feet in 3 different positions (together side-by-die, semi-tandem, \& tandem), two timed trials of a 4-meter walk, and time to rise from a chair 5 times. During the TUG, subjects will complete the following physical assessment - time to rise from a chair, walk 3 meters, return, \& sit down. This assessment will be performed by trained study team members. 6-month Phone Call:
- PROMIS Physical Function
- Barthel Activities of Daily Living Index
- Residence at a nursing home
- Conditions
- Femoral Fracture, Fragility Fracture, Muscle Atrophy
- Being tested
- Essential Amino Acid Supplementation
- Medical subject headings
- Femoral Fractures, Muscular Atrophy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Essential Amino Acid SupplementationCombination product
Also called MEND Repair & Recover
Powdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB)
| Study group | Role | What they receive |
|---|---|---|
| Essential Amino Acid Supplementation | Experimental | Subjects randomized to intervention arm of this study will receive essential amino acid (EAA)-based oral nutrition supplementation in addition to standard of care postoperative nutrition. Subjects will take 1 scoop (26.7g) of supplement twice daily for 4 weeks after injury. Supplementation will begin within 72 hours of surgical fixation. The EAA-based supplement used in this clinical trial is MEND™ Repair and Recover®. Receives: Combination Product: Essential Amino Acid Supplementation |
| Standard of Care Postoperative Nutrition | No intervention | Subjects randomized to the control arm of this study will receive no intervention. They will receive standard of care postoperative nutrition. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentration and average count of satellite cells, myonuclei, M1, and M2 Macrophages for Type 1 and Type 2 fibers
Biopsy results will provide the counts and averages by Type I and Type II fibers for satellite cells, myonuclei, M1 and M2 macrophages.
Measured: Day of Surgery, 3 weeks
Cross sectional concentration of Type 1 and Type 2 muscle fibers
Biopsy results will provide the Type I and Type II muscle fiber cross sectional area in µm2.
Measured: Day of Surgery, 3 weeks
Concentration of myostatin, interleukin-6, and tumor necrosis factor alpha
Through serum analysis levels of myostatin, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) will be measured in pg/mL.
Measured: Day of Surgery, 3 weeks
Concentration of c-terminal agrin fragments
Through serum analysis levels of c-terminal agrin fragment will be measured in ng/mL.
Measured: Day of Surgery, 3 weeks
Secondary outcomes (6)
Change in skeletal muscle
Change in the amount of skeletal muscle mass will be measured by the InBody S10 Body Composition Analyzer and recorded in kilograms.
Measured: Postoperative day 1, 3 weeks, 6 weeks, 12 weeks
Measurement of lower extremity functioning in older adults
Physical performance in relation to lower extremity function will be measured by the Short Physical Performance Battery (SPPB) 14. Individuals are scored on a scale ranging from 0 (worst performance) to 12 (best performance) based on their walking speed, ability to do chair stands, and standing balance.
Measured: 12 weeks
Assessment of mobility, balance, walking ability, and fall risk in older adults
Physical performance in relation to mobility, balance, walking ability and fall risk will be measured by the Timed Up \& Go (TUG) 15 test. For this test, the research coordinator measures the time required for a participant to rise from an armchair (45 cm height), walk 3 m and return to the chair. Longer times can indicate higher possibility of falling.
Measured: 12 weeks
Measurement of self-reported physical capability
Patient-reported physical performance will be measured using the PROMIS-Physical Function survey. PROMIS measures are scored on the T-score metric. a high score means the individual self-reports more of a capability at a certain activity.
Measured: Post operative day 1, 3 weeks, 6 weeks, 12 weeks, 6 months
Measurement of self-reported ability to complete activities of daily living (ADL)
Patient-reported physical performance of activities of daily living will be measured using the Barthel Activities of Daily Living Index. It is a commonly used measure of activities of daily living outcomes for older adults. It measures the ability to perform activities of daily living that are important for maintaining function including feeding, bathing, grooming, dressing, bowel control, bladder control, toilet use, transfers from bed to chair and back, mobility on level surfaces, and stairs. Each measure is assessed on a 10-point scale, all scores are combined to give a score out of 100 points. The higher the score the more independent the individual.
Measured: Preoperative, 3 weeks, 6 weeks, 6 months
Assessment of independent or communal living
Residence at a nursing home or living independently will be recorded at each follow-up visit. Participants living in an assisted living home (apartment or condominium with nursing assistance on call), apartment, single family home, or family member's home are considered living in the community. Living without assistance in a single dwelling will be considered living independently.
Measured: Preoperative, 3 weeks, 6 weeks12 weeks, 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2023
- Study start17 Jun 2024
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Femoral FractureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Michael C Willey
- Sponsor type
- University, hospital or other
- Collaborators
- MEND, Slocum Research & Education Foundation
- Responsible party
- Sponsor-investigator, Michael C Willey, University of Iowa
- Investigators
- Michael C Willey, MD, Principal investigator, University of Iowa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06050668
- Sponsor's protocol ID
- 202307209-1
- Status last verified
- Oct 2026
- First submitted
- 28 Aug 2023
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MEND Repair & Recover Clinical Trial
- ClinicalTrials.gov ID
- NCT06050668
- Acronym / sponsor ID
- 202307209-1
- Conditions
- Femoral Fracture, Fragility Fracture, Muscle Atrophy
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Michael C WilleyUniversity, hospital or other
- Collaborators
- MEND, Slocum Research & Education Foundation
- Study start
- 17 Jun 2024 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 22 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.
Detailed description
This study consists of 7 study visits that occur over 6 months after operative fixation of femoral fragility fracture. Consenting participants will be asked to complete the study assessments/procedures at the time points described below. Patients will be treated with operative fixation of their fracture per standard of care.
Preoperative
- Mini-Mental State Examination (MMSE-2®): This is a screening tool for cognitive impairment and will be used to determine eligibility for the study.
- Subjects will be randomized to the intervention arm or control arm in a 1:1 ratio. Subjects randomized to the control arm will receive standard of care nutrition during hospital admission. Subjects randomized to intervention arm of this study will receive essential amino acid (EAA)-based oral nutrition supplementation in addition to standard of care nutrition. Subjects will take the supplement twice daily for 4 weeks after injury. Supplementation will begin within 72 hours of surgical fixation.
Day of Surgery (DOS):
- Muscle Biopsy: Bilaterial biopsies will be obtained from the superficial vastus lateralis muscle on the injury extremity. Biopsies will be performed by board-certified orthopedic surgeons.
- Systemic Inflammatory Labs: A sample of about 15 mL of peripheral venous blood will be obtained by trained clinical staff.
Postoperative Day 1 (POD 1)
- Body composition: Will be assessed using a bioelectrical impedance analysis (BIA) device (InBody S10 Body Composition Analyzer). This is non-invasive test that uses a low-level imperceptible electrical current to measure body composition and body water. In a supine position, electrodes are placed on the hands and ankles of the subjects and the result is recorded in the BIA device. This assessment will be performed by trained study team members.
- Visual Analog Scale (VAS): This is a survey to report on subjective pain.
- Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function: This is a survey that asks subjects to report on subjective measures of pain and physical function. This survey is a computer adaptive test that is completed in REDCap® using a tablet or computer. Subjects will self-administer this survey
- Mini Nutrition Assessment (MNA): This is a survey designed for elderly patients to identify malnourishment or risk thereof. This survey is a computer adaptive test that is completed in REDCap® using a tablet or computer.
- Protein Screener: This is a survey designed for older adults to screen for low protein intake. This survey is a computer adaptive test that is completed in REDCap® using a tablet or computer.
- Barthel Activities of Daily Living Index is a commonly used measure of activities of daily living outcomes for older adults. It measures the ability to perform activities of daily living that are important for maintaining function including feeding, bathing, grooming, dressing, bowel control, bladder control, toilet use, transfers from bed to chair and back, mobility on level surfaces, and stairs. Each measure is assessed on a 10-point scale, all scores are combined to give a score out of 100 points. The higher the score the more independent the individual.
- Residence at a nursing home will be recorded at each follow up visit. Participants living in an assisted living home (apartment or condominium with nursing assistance on call), apartment, single family home, or family member's home are considered living in the community.
- Patients will be given an adverse event log to track any side effects or falls. We will encourage patients to call us but would like them to have a note sheet in case they forget.
- Patients randomized to the supplement group will be given a take home supplement log where they will track their AM and PM doses.
- All patients will be given logs to keep track of their daily pain, PT and number of meals eaten. 3 Week Clinic Visit:
- Muscle biopsies
- Systemic inflammatory labs
- Body composition: InBody S10 Body Composition Analyzer
- Visual Analog Scale (VAS)
- Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function
- Barthel Activities of Daily Living Index
- Residence at a nursing home.
- Supplement Compliance: Patients will be asked to return completed log sheets and if they were randomized to the supplement group, being in their supplement containers to be weighed. 6-Week Clinic Visit:
- Body composition: InBody S10 Body Composition Analyzer
- Visual Analog Scale (VAS)
- PROMIS Physical Function
- Barthel Activities of Daily Living Index
- Residence at a nursing home
- Supplement compliance 12-week Clinic Visit:
- Body composition: InBody S10 Body Composition Analyzer
- Visual Analog Scale (VAS)
- PROMIS Physical Function
- Mini Nutrition Assessment (MNA)
- Protein Screener
- Barthel Activities of Daily Living Index
- Residence at a nursing home
- Physical Performance Measures: Objective measures of physical performance (mobility, strength, power, \& balance) will be assessed with the Short Physical Performance Battery (SPPB)14 and the Timed Up \& Go (TUG)15 test. During the SPPB, subjects will complete the following physical assessments - ability to stand for 10 seconds with feet in 3 different positions (together side-by-die, semi-tandem, \& tandem), two timed trials of a 4-meter walk, and time to rise from a chair 5 times. During the TUG, subjects will complete the following physical assessment - time to rise from a chair, walk 3 meters, return, \& sit down. This assessment will be performed by trained study team members. 6-month Phone Call:
- PROMIS Physical Function
- Barthel Activities of Daily Living Index
- Residence at a nursing home
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Essential Amino Acid Supplementation | Experimental | Combination Product: Essential Amino Acid SupplementationSubjects randomized to intervention arm of this study will receive essential amino acid (EAA)-based oral nutrition supplementation in addition to standard of care postoperative nutrition. Subjects will take 1 scoop (26.7g) of supplement twice daily for 4 weeks after injury. Supplementation will begin within 72 hours of surgical fixation. The EAA-based supplement used in this clinical trial is MEND™ Repair and Recover®. |
| Standard of Care Postoperative Nutrition | No intervention | –Subjects randomized to the control arm of this study will receive no intervention. They will receive standard of care postoperative nutrition. |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (6 listed)
- Hospital inpatient
- Age ≥ 65 years old on admission
- Low-energy mechanism of injury
- Diagnosis of femur fracture (OTA 31, 32, or 33 fracture)
- Indicated for surgical fixation
Key exclusion criteria (8 listed)
- Part of a vulnerable population (ex: Incarcerated, Non-English speaking)
- Cognitive impairment (MMSE score ≤ 17)
- Electrical medical implant (ex: Pacemaker/Defibrillator, Left Ventricular Assist Device, Cochlear implant, Insulin pump, Pain medication pumps, Spinal cord stimulator)
- Non-ambulatory prior to injury
- Inability to consume an oral diet or allergy to supplement ingredients (ex: milk allergy)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Essential Amino Acid SupplementationAlso: MEND Repair & RecoverPowdered supplement that can be mixed into beverage of choice. Ingredients: Zinc, Vitamin A, Vitamin C, Whey Protein, Leucine, Calcium, Vitamin D, Glutamine, Boron, Turmeric, Bioperine, Iron, β-hydroxy β-methylbutyrate (HMB) | Combination product | Essential Amino Acid Supplementation |
Primary outcome
Concentration and average count of satellite cells, myonuclei, M1, and M2 Macrophages for Type 1 and Type 2 fibers
Time frame: Day of Surgery, 3 weeks
Biopsy results will provide the counts and averages by Type I and Type II fibers for satellite cells, myonuclei, M1 and M2 macrophages.
Cross sectional concentration of Type 1 and Type 2 muscle fibers
Time frame: Day of Surgery, 3 weeks
Biopsy results will provide the Type I and Type II muscle fiber cross sectional area in µm2.
Concentration of myostatin, interleukin-6, and tumor necrosis factor alpha
Time frame: Day of Surgery, 3 weeks
Through serum analysis levels of myostatin, interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) will be measured in pg/mL.
Concentration of c-terminal agrin fragments
Time frame: Day of Surgery, 3 weeks
Through serum analysis levels of c-terminal agrin fragment will be measured in ng/mL.
6 secondary outcomes
Change in skeletal muscle
Time frame: Postoperative day 1, 3 weeks, 6 weeks, 12 weeks
Measurement of lower extremity functioning in older adults
Time frame: 12 weeks
Assessment of mobility, balance, walking ability, and fall risk in older adults
Time frame: 12 weeks
Measurement of self-reported physical capability
Time frame: Post operative day 1, 3 weeks, 6 weeks, 12 weeks, 6 months
Measurement of self-reported ability to complete activities of daily living (ADL)
Time frame: Preoperative, 3 weeks, 6 weeks, 6 months
Assessment of independent or communal living
Time frame: Preoperative, 3 weeks, 6 weeks12 weeks, 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Femoral Fracture
Not yet recruiting
Lumbar Erector Spinae Plane Block Versus PENG Block for Hip Fracture Surgery
Femur Neck Fracture, Hip Fractures
Active, not recruiting
Lumbar-Sacral Plexus Block vs Fascia Iliaca Block Plus Low-Dose Spinal Anesthesia for Femoral Neck Fracture Surgery
Femoral Neck Fractures, Nerve Block
Not yet recruiting
Magnesium-Titanium Hybrid Intramedullary Nail System For Long Bone Fractures
Tibial Fracture, Femoral Fracture
RecruitingObservational study
Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures
Fracture; Pelvic, Insufficiency Fractures
Enrolling by invitationObservational study
GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)
Osteoporosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Michael C Willey, MD principal investigator
University of Iowa
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Essential Amino Acid Supplementation in people with Femoral Fracture and Fragility Fracture, run by Michael C Willey at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Michael C Willey, MD (319-384-8452, michael-willey@uiowa.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentration and average count of satellite cells, myonuclei, M1, and M2 Macrophages for Type 1 and Type 2 fibers (time frame: Day of Surgery, 3 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.